On the afternoon of March 29, our Chairman Shi Yuanyuan, Chief Scientist Wang Jianxun, Deputy General Manager Tang Xiaomeng, and Deputy Head of R&D Sun Rui visited Shanghai Nkarta Cell Technology Co., Ltd. (hereinafter referred to as "Nkarta") for exchange and discussion. Nkarta President Xiao Weihua, CEO Tang Xiaodong, Executive Director of Strategic Development Zhang Cai, and R&D Director Wang Ting extended a warm welcome and held a symposium.

Nkarta and Shenzhen Cell Valley began comprehensive strategic cooperation in September 2022 to jointly advance new drug R&D in the CAR-NK field. During this symposium, Professor Xiao Weihua introduced Nkarta's current production and R&D progress. The two parties discussed the progress and technical issues related to existing collaborative projects and clarified next steps and cooperation plans.

About Shanghai Nkarta Cell Technology Co., Ltd. (Nkarta)

Shanghai Nkarta Cell Technology Co., Ltd. (Nkarta) is a biotechnology company focused on the R&D of innovative immune cell therapy technologies. Building on over 30 years of team exploration in NK cell basic biology, preclinical research, and clinical translation, Nkarta is committed to becoming a world-leading cell therapy company with a deep understanding of NK cells and their frontier technologies. The company possesses proprietary technologies including allogeneic peripheral blood NK cell expansion and cryopreservation, genetic modification, and a clinical "off-the-shelf" ABCDE-NK strategic platform. Through synthetic immunology strategies such as a logic-gate gene circuit technological chassis, Nkarta achieves intelligent editing of NK cells, enabling precise targeting of cancer cells, precise adaptation to the tumor microenvironment, and precise matching of donor-recipient effector/target cells.

Guided by the goal of addressing major clinical disease treatment challenges and achieving precision immunotherapy, Nkarta has developed a series of original intelligent NK cell products. The company strives to build an immune cell drug enterprise that continuously breaks through core technologies and maintains international leadership, establishing itself as a source of next-generation NK cell therapy technologies and products globally, and becoming a banner for China in leading the world.